Do you want to read an article? Please log in or register.
Unusual presentation of metastatic breast cancer to the bladder
Breast Cancer
Related content
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
COMMENTED
Breast Cancer
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer
★ 0
Recommended and commented by
Dr Andreas Müller, Faculty Member
Clin Breast Cancer
Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK)
doi: 10.1016/j.clbc.2025.05.015
SABCS 2025
Breast Cancer
DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer
SABCS 2024
Breast Cancer
Advancing Breast Cancer Treatment with Elacestrant
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
Eur J Cancer
Milano M, Valenza C, Ferrari A, Gandini S, Trapani D, Santoro C, Battaiotto E, Carnevale Schianca A, Giordano E, Katrini J, Castellano G, Taurelli Salimbeni B, Leonardi MC, Dicuonzo S, Criscitiello C, Bianco N, Dellapasqua S, Munzone E, Curigliano G, Colleoni M, Jereczek-Fossa BA
doi: 10.1016/j.ejca.2024.115164
COMMENTED
Breast Cancer
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Natl Cancer Inst
Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, O'Meara T, Grinda T, Morganti S, Waks AG, Winer EP, Lin NU, Krop IE, Tolaney SM, Sammons S, Lustberg M
doi: 10.1093/jnci/djaf220
Breast Cancer
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry
Int J Cancer
Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, Decker T
doi: 10.1002/ijc.35296